Improvement of drug therapy safety for oncological patients in the inpatient sector by a pharmacist embedded in a multiprofessional healthcare team.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00026729

Enrollment

148

Registered

2021-12-01

Start date

2020-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

medication errors

Interventions

Group 1: Control group: data collection of medication errors by viewing patient files. There was no pharmacist on ward during the investigated period. Group 2: Intervention group 1: intervention phas

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients diagnosed with C00-D48 or D50-D90. Patients of the tumor clinic of the Fulda Clinic gAG. Ward stay = 72 h. P2: ward pharmacist naive for six months before starting P2.

Exclusion criteria

Exclusion criteria: No saved temperature curve (incomplete documentation). < six medication lines per stay. Patients are not cared for by an oncologist.

Design outcomes

Primary

Measure	Time frame
Reduction of medication errors through the work of a ward pharmacist.	—

Secondary

Measure	Time frame
Reduction of quantity / costs for selected drugs (excluding chemotherapeutic agents and antibodies). Time savings on the ward by working according to standards in the various intervention phases. Compliance with developed / existing therapy standards.	—

Countries

Germany

Contacts

Public ContactSvenja Dierkes

Klinikum Fulda gAG

svenja.dierkes@klinikum-fulda.de0661846431

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026